# Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

> **NCT01515189** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 831 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT01515189
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-17
- **Primary completion:** 2016-02-06
- **Final completion:** 2017-08-17
- **Target enrollment:** 831 (ACTUAL)
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01515189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01515189, "Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01515189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*